WuXi AppTec mulls gene unit sale to soften U.S. legal blow
Market talk is swirling that WuXi AppTec may be preparing to shed its cell and gene therapy business to limit potential exposure to U.S. biosecurity legislation Key Takeaways: The drug…
Recent Articles
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
-
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK 2359.HK
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
